Marinomed Advances Tacrolimus Eyedrops to Compounding Market

Marinomed Biotech AG, based in Austria, announces progress with its Tacrolimus eyedrops for the compounding market. The product aims to meet the high medical needs identified by ophthalmologists in the USA and Europe for treating refractory ocular inflammation and reducing steroid dependency. Marinomed anticipates first revenues by late 2026 or early 2027.

This strategic move marks a commercial milestone for Marinomed, leveraging its Marinosolv® platform. The technology could cater to niche patient populations and address unmet needs more swiftly than traditional drug development pathways. The Marinosolv-based Tacrolimus solution has demonstrated efficacy at significantly lower concentrations, offering a superior alternative to existing options.

Potential applications for the eyedrops include various ocular diseases and conditions that are unaddressed by current therapies. By entering the compounding market, Marinomed hopes to generate significant growth and development opportunities.